Due to a limited supply, we are unable to accept phone calls to schedule COVID-19 vaccinations.
For the most up-to-date information, please check our COVID-19 Vaccination Website.

 

Additional Coronavirus Updates >

MENU

Alexander Kutikov, MD, FACS

A. Kutikov, MD, FACS

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

Secondary Location

Fox Chase Cancer Center Huntingdon Pike
8 Huntingdon Pike
Rockledge, PA 19046

About

Chief, Division of Urology and Urologic Oncology

Professor, Department of Surgical Oncology

Roberta R. Scheller Chair in Urologic Oncology

American Urological Association's Urology Care Foundation, Prostate Health Committee Panel Member

Treatment Focus

Minimally Invasive Surgery, Robotic Surgery, Laparoscopic Surgery, Traditional Open Surgery
Prostate Cancer: robotic and open radical nerve-sparing prostatectomy
Bladder Cancer: urinary diversion, orthotopic neobladder reconstruction
Kidney Cancer: kidney-sparing approaches, robotic, laparoscopic, open kidney surgery.
Adrenal masses: minimally-invasive adrenal surgery and extensive expertise in treatment of adrenal incidentalomas.

Research Program

Key Awards

Philadelphia Magazine Top Docs 2020
     Urology

Language(s) Other than English

Russian

Treatment Philosophy

I am a surgical specialist who treats tumors of the adrenal, kidney, prostate, bladder, testis, and other genitourinary organs. Working closely with other members of the Fox Chase multidisciplinary team, I make certain that my patients are aware of all the choices that today's cutting edge oncological care has to offer, regardless of whether these treatments take place inside or outside the operating room.

When surgery is necessary, I strive to offer the best operation that fits an individual's particular condition and circumstance. Indeed, my unique fellowship training in both traditional open surgery and minimally-invasive approaches such as laparoscopy and robotics, allows me to offer a wide range of options that optimize oncological outcomes and minimize recovery time. For example, I am skilled at both open and robot-assisted nerve-sparing prostatectomy and open, laparoscopic, and robotic kidney surgery. Particularly, I have advanced expertise in kidney preservation. For patients with bladder cancer, I am able to offer both bladder-sparing approaches and the latest techniques in continent urinary reconstruction. Furthermore, I have a particular interest and expertise in treatment of various tumors and conditions that stem from the adrenal gland.

As a clinician at an academic institution such as Fox Chase, I actively participate in medical research. In particular, my academic interests focus on kidney, prostate, bladder, and adrenal disease. Being an active contributor to the medical literature, I hope to offer my patients the most up-to-date information on medical progress and, if necessary, help them enroll into appropriate clinical trials — many of which are only available through Fox Chase.

Modern oncology offers patients tremendous hope; however, today's treatment options can be overwhelming, especially to those who are trying to cope with the shock of a recent cancer diagnosis. I greatly appreciate the toll that such a diagnosis can take not only on the patient, but also on his or her family. I hope to bring to every one of my patients a sense of understanding and compassion that can help us effectively work together to achieve the best outcome that modern medicine has to offer.

Education and Training

Educational Background

  • Fellow, Society of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
  • Chief Resident, Urology, University of Pennsylvania, Philadelphia, PA, 2007-2008
  • Resident, Urology, University of Pennsylvania, Philadelphia, PA, 2004-2007
  • MD, Harvard Medical School, Harvard-MIT Health Sciences and Technology Program, Boston, MA, 2003

Certifications

  • American Board of Urology, Board Certified

Memberships

  • Society of Urologic Oncology
  • American Urological Association
  • American College of Surgeons
  • Philadelphia Urological Society

Honors & Awards

  • Philadelphia Magazine Top Doctors, 2017-20
  • Best Doctors in America® , 2019-2020, Urology
  • Everyday Hero Award, Pennsylvania Medical Society (PAMED), 2018
  • America's Top Doctors®2016-17
  • BJU International Journal Best Mobile App Award for drawMD Urology iPad Application, American Urological Association Meeting, San Diego, CA, 2013
  • Mid-Atlantic AUA Young Investigator Representative to the AUA’s Research Forum, American Urological Association Meeting, Washington, DC, 2011
  • CaPSURE Scholar, CaPSURE Scholars Program in Prostate Cancer Outcomes Research, 2009-10
  • American College of Surgeons Excellence in Research Award 96th Annual Clinical Congress, Surgical Forum, 2010
Patient Stories

Annie Dunn

Kidney Cancer

Annie Dunn

Kidney Cancer

I have always enjoyed being social and keeping busy with a handful of hobbies. At 68, I spent most of my time cycling with my husband Tom, going on walks, reading whatever I could find, and socializing with friends. Up until recently, those things had always been a regular part of my life. However, after being diagnosed with kidney cancer amid the COVID-19 pandemic, those activities had to take a back seat.

Thomas Nixon

Kidney Cancer

Thomas Nixon

Kidney Cancer

I never expected what I heard, that my cancer was aggressive. I went back to my primary care doctor and asked if I should get a second opinion. He told me I should, so I was referred to Dr. Alexander Kutikov, a surgical oncologist at Fox Chase Cancer Center. This was all during the time that COVID-19 was beginning to ramp up in the United States. I was concerned that my surgery would be rescheduled or even canceled.

Tom Maguire

Bladder Cancer

Tom Maguire

Bladder Cancer

"In 2018 I was diagnosed with muscle invasive bladder cancer, which seemed like it would end my diving, but also provided me a new way to give back."

Thomas Myers

Melanoma;  Prostate Cancer

Thomas Myers

Melanoma;  Prostate Cancer

The level of teamwork and communication amongst the doctors was reassuring. Even though I felt overwhelmed by multiple surgeries, treatments, and diagnoses, I took immense comfort in the prompt actions taken my team of physicians.

Barry Taitelman

Kidney Cancer

Barry Taitelman

Kidney Cancer

Becoming a grandfather was something I had been looking forward to for years. But just before I learned that my daughter-in-law was pregnant, I was diagnosed with Stage 4 kidney cancer. I couldn’t bear the thought of getting to know my grandson and then not getting to be there to watch him grow up.

Pages

Research Profile

Research Program

Research Interests

Dr. Kutikov has authored over 140 peer-reviewed publications.  His current research interests include understanding carcinogenesis of genitourinary cancers, risk-stratification of surgical outcomes, and quantification of competing risks.  He serves on editorial boards of academic journals, including being the Associate Editor of Digital Media for European Urology, the field of Urology's leading academic publication.

Dr. Kutikov also has significant interests in harnessing web and mobile technology to improve patient engagement and quality of care.  He is a co-founder of several ventures that strive to improve physician education and patient care.  

Lab Overview

In collaboration with Vladimir Kolenko, MD, PhD, and Robert Uzzo, MD, our research efforts span the basic and the clinical sciences. Our work focuses on understanding the process of renal and prostatic carcinogenesis and assessing novel therapeutic regimens for the treatment of urological cancers.

As part of our work, we explore the role of zinc in development and progression of prostate malignancy.  Zinc concentrations diminish early in the course of prostate carcinogenesis—prior to histopathological changes—and continue to decline during progression toward castration-resistant growth. The objective of research in our laboratory is to test and advance an emerging paradigm that intracellular zinc deficiency augments malignant potential of prostate cancer cells and, therefore, promotes prostate tumorigenesis. We are also investigating the role of zinc chelators as potential therapeutic agents for the treatment of castration-resistant prostate cancer. Work performed by Dr. Kolenko indicates that treatment of prostate cancer cells with the zinc chelating agent TPEN induces selective down-regulation of X-linked inhibitor of apoptosis protein (XIAP) and sensitizes cancer cells to cytotoxic agents. Importantly, the observed effect is not limited to prostate cancer, as TPEN reduces expression of XIAP in malignant cell lines of various origins, e.g. colon, ovarian, leukemia, breast and cervical.

The second major theme of our research is to determine the mechanism of tyrosine kinase inhibitor (TKIs)-resistance in genitourinary tumors. Our studies reveal that TKI-resistance coincides with the loss of phosphatase and tensin homolog (PTEN) protein expression in prostate and renal malignant cells. On the contrary, expression of PTEN sensitizes prostate and renal tumors to multi-targeted tyrosine kinase inhibitor sunitinib both in vitro and in vivo. In addition, our studies indicate that an increase in expression of IL-6 and IL-8 correlates with sunitinib and pazopanib resistance in prostate and renal tumor cells. Use of a reliable biomarker for TKI response, harbors promise both in the clinical and research settings.

In the clinical arena, we focus our efforts on addressing quantification of competing risks of death for patients with urologic malignancies, investigating the biology and natural history of small renal masses, improving reporting and risk-stratification of surgical outcomes for patients with kidney cancer, and addressing clinical approaches to patients with adrenal cancers and incidental adrenal masses.

Publications

Selected Publications

A. G. McIntosh, D. C. Parker, B. L. Egleston, R. G. Uzzo, H. Haseebuddin, S. S. Joshi, R. Viterbo, R. E. Greenberg, D. Y. T. Chen, M. C. Smaldone, and Kutikov, “Prediction of Significant Estimated Glomerular Filtration Rate Decline Following Renal Unit Removal to Aid in the Clinical Choice between Radical and Partial Nephrectomy in Patients with Renal Mass and Normal Renal Function,” BJU Int, May 2019. PubMed

H. Borgmann, M. Cooperberg, D. Murphy, S. Loeb, J. N’Dow, M. J. Ribal, H. Woo, M. Rouprêt, A. Winterbottom, C. Wijburg, M. Wirth, J. Catto, and A. Kutikov, “Online Professionalism—2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media,” European Urology, pp. 1–7, Aug. 2018. PubMed

M. C. Smaldone, B. Egleston, J. M. Hollingsworth, B. K. Hollenbeck, D. C. Miller, T. M. Morgan, S. P. Kim, A. Malhotra, E. Handorf, Y.-N. Wong, R. G. Uzzo, and A. Kutikov, “Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data,” Med Care, vol. 55, no. 4, pp. 398–404, Apr. 2017. PubMed

N. Waingankar, K. Mallin, M. Smaldone, B. L. Egleston, A. Higgins, D. P. Winchester, R. G. Uzzo, and A. Kutikov, “Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy,” BJU Int, vol. 120, no. 2, pp. 239–245, Aug. 2017. PubMed

B. T. Ristau, D. Y. T. Chen, J. Ellis, A. Malhotra, L. DeMora, R. B. Parsons, B. Milestone, M. Brody, R. Viterbo, R. Greenberg, M. Smaldone, R. Uzzo, J. Anaokar, and A. Kutikov, “Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy,” The Journal of Urology, Oct. 2017. PubMed

S. P. Kim, S. C. Campbell, I. Gill, B. R. Lane, H. Van Poppel, M. C. Smaldone, A. Volpe, and A. Kutikov, “Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses,” European Urology, vol. 72, no. 1, pp. 64–75, Jul. 2017. PubMed

A. Kutikov, H. H. Woo, and J. W. Catto, “Urology Tag Ontology Project: Standardizing Social Media Communication Descriptors,” European Urology, vol. 69, no. 2, pp. 183–185, Feb. 2016. PubMed

A. Kutikov, M. C. Smaldone, R. G. Uzzo, M. Haifler, G. Bratslavsky, and B. C. Leibovich, “Renal Mass Biopsy: Always, Sometimes, or Never?,” European Urology, vol. 70, no. 3, pp. 403–406, Sep. 2016. PubMed

E. R. Plimack, R. L. Dunbrack, T. A. Brennan, M. D. Andrake, Y. Zhou, I. G. Serebriiskii, M. Slifker, K. Alpaugh, E. Dulaimi, N. Palma, J. Hoffman-Censits, M. Bilusic, Y.-N. Wong, A. Kutikov, R. Viterbo, R. E. Greenberg, D. Y. T. Chen, C. D. Lallas, E. J. Trabulsi, R. Yelensky, D. J. McConkey, V. A. Miller, E. A. Golemis, and E. A. Ross, “Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer,” European Urology, vol. 68, no. 6, pp. 959–967, Dec. 2015. PubMed

S. Ginzburg, R. Uzzo, J. Walton, C. Miller, D. Kurz, T. Li, E. Handorf, R. Gor, A. Corcoran, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, M. C. Smaldone, and A. Kutikov, “Residual Parenchymal Volume, Not Warm Ischemia Time, Predicts Ultimate Renal Functional Outcomes in Patients Undergoing Partial Nephrectomy.,” Urology, vol. 86, no. 2, pp. 300–306, Aug. 2015.   PubMed

B. Shuch, A. Amin, A. J. Armstrong, J. N. Eble, V. Ficarra, A. Lopez-Beltran, G. Martignoni, B. I. Rini, and A. Kutikov, “Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity,” European Urology, vol. 67, no. 1, pp. 85–97, Jan. 2015. PubMed

E. R. Plimack, J. H. Hoffman-Censits, R. Viterbo, E. J. Trabulsi, E. A. Ross, R. E. Greenberg, D. Y. T. Chen, C. D. Lallas, Y.-N. Wong, J. Lin, A. Kutikov, E. Dotan, T. A. Brennan, N. Palma, E. Dulaimi, R. Mehrazin, S. A. Boorjian, W. K. Kelly, R. G. Uzzo, and G. R. Hudes, “Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity,” J. Clin. Oncol., vol. 32, no. 18, pp. 1895–1901, Jun. 2014. PubMed

A. Minervini, M. Carini, R. G. Uzzo, R. Campi, M. C. Smaldone, and A. Kutikov, “Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surface-Intermediate-Base Margin Score.,” European Urology, Jun. 2014.    PubMed

A. Kutikov, P. Makhov, K. Golovine, D. J. Canter, M. Sirohi, R. Street, J. Simhan, R. G. Uzzo, and V. M. Kolenko, “Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer,” Urology, vol. 78, no. 4, pp. 968.e7–11, Oct. 2011. PubMed

A. Kutikov, M. C. Smaldone, B. L. Egleston, B. J. Manley, D. J. Canter, J. Simhan, S. A. Boorjian, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, and R. G. Uzzo, “Anatomic Features of Enhancing Renal Masses Predict Malignant and High-Grade Pathology: A Preoperative Nomogram Using the RENAL Nephrometry Score,” European Urology, vol. 60, no. 2, pp. 241–248, Aug. 2011.   PubMed

A. Kutikov, B. L. Egleston, Y.-N. Wong, and R. G. Uzzo, “Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram,” J. Clin. Oncol., vol. 28, no. 2, pp. 311–317, Jan. 2010. PubMed

A. Kutikov and R. G. Uzzo, “The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth,” The Journal of Urology, vol. 182, no. 3, pp. 844–853, Sep. 2009. PubMed

Additional Publications

Full List of Publications

Ratings

440 PATIENT SATISFACTION REVIEWS

Our Patient Satisfaction Rating is an average of all responses to care provider related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more.

OVERALL RATING

4.9 / 5.0

RATINGS BREAKDOWN

  • 5.0
  • 5.0
  • 5.0
  • 4.9
  • 4.9

82 PATIENT COMMENTS

  • No Star Ratings Available November 29, 2020
    Perfect
  • 5.0
    November 29, 2020
    From the office staff all the way through to the doctor himself I was treated friendly and professional and all of my health concerns were addressed. Great staff - Great doctor.
  • 5.0
    November 28, 2020
    As always, Dr Kutikov and his staff were wonderful
  • 5.0
    November 28, 2020
    Dr Kutikov and his staff are the best!
  • No Star Ratings Available November 28, 2020
    I feel comfortable to be treated by Dr. Kutikov.
  • 5.0
    November 23, 2020
    always very professional. feel very at ease here. My Dr. is AWESOME!!!!
  • No Star Ratings Available November 21, 2020
    good discussion. covered points I needed to talk about.
  • 5.0
    November 13, 2020
    I love Fox Chase and Dr Kutikov and his team , I feel that I am in the best care and hands with both ...
  • 5.0
    November 13, 2020
    my opinion the doctor Kutokow is the best. I can't find anyone better than him and his staff. Thanks
  • No Star Ratings Available November 11, 2020
    He explained everything I needed to know.
  • No Star Ratings Available November 06, 2020
    j found him very responsive
  • 5.0
    October 20, 2020
    Everyone, provider and his team, receptionists, MRI staff, very professional and caring.
  • No Star Ratings Available October 16, 2020
    Dr. was extremely knowledgeable, helpful, and professional as well as compassionate and considerate.
  • No Star Ratings Available October 12, 2020
    Dr Kutikov was terrific in every way and took plenty of time with us
  • No Star Ratings Available October 09, 2020
    Dr kutikov is great! friendly, welcoming and puts you at ease. makes you feel like family
  • 5.0
    October 05, 2020
    This visit was completed virtually, spent 30 minutes with nurse, 20 minutes with one Doctor, and 20 minutes with Dr. Kutikov. Everyone was very cordial, pleasant, took there time to answer my questions and clearly explained the next steps I would be taking. I was very impressed with everyone I spoke with. [...]
  • 5.0
    October 04, 2020
    The best care!
  • 5.0
    September 26, 2020
    As you can see, the care that I received via tele. was outstanding. Everyone, from the first person I spoke to in order to schedule an appt. with the Dr. was awesome, as was the Dr. All were very professional and made me feel comfortable. Would definitely recommend Fox Chase to anyone that needed to speak to the professionals. It was a pleasure to speak with all concerned.
  • 5.0
    September 18, 2020
    visit was a consultation. dr was very informative and took time to explain my options. very happy with the visit which was a tele hookup.
  • 5.0
    August 27, 2020
    I have a very good experience!
LOAD MORE

Connect with Fox Chase